Resultados da busca - Ole Gadeberg

  • Mostrando 1 - 4 resultados de 4
Refinar Resultados
  1. 1
    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma

    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma por Myron S. Czuczman, Georg Heß, Ole Gadeberg, Lars Møller Pedersen, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Claus Strange, Kristian Windfeld, Andreas Viardot

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

    Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vinc... por Tina Green, Ken H. Young, Carlo Visco, Zijun Y. Xu‐Monette, Attilio Orazi, Ronald S. Go, Ole Nielsen, Ole Gadeberg, Torben Mourits‐Andersen, Mikael Frederiksen, Lars Møller Pedersen, Michael Møller

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

    First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial por Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Z. Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Folden Flensburg, Jørgen Holm Petersen, Nedjad Losic, John Radford

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20<sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

    Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20<sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS... por Laurie H. Sehn, André Goy, Fritz Offner, Giovanni Martinelli, Marı́a Dolores Caballero, Ole Gadeberg, Tara Baetz, Andrew D. Zelenetz, Gianluca Gaïdano, Luis Fayad, Rena Buckstein, Jonathan W. Friedberg, Michael Crump, Branimir Jakšić, Pier Luigi Zinzani, Swaminathan P. Iyer, Deniz Şahin, Akiko Chai, Günter Fingerle‐Rowson, Oliver W. Press

    Publicado em 2015
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: